Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Background Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB). However, little is known about the implications of dupilumab for cancer outco...

Full description

Saved in:
Bibliographic Details
Main Authors: Shadmehr Demehri, Kerry L Reynolds, Yevgeniy R Semenov, Matthew Tran, Nicole R LeBoeuf, Suzanne Xu, Guihong Wan, Bonnie W Leung, Emma Beagles, Sara Khattab, Cameron Moseley, Chuck Lin, Marjan Azin, Ninghui Hao
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e010638.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e010638.full

Similar Items